Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker MCRB. The company is focused on developing biotherapeutic candidates for serious diseases, with work centered on live biotherapeutic products designed to influence the gut microbiome, strengthen gastrointestinal barrier function, and help regulate immune responses. Its pipeline includes SER-155, which is being studied for the prevention of bacterial bloodstream infections and related complications in patients undergoing allogeneic hematopoietic stem cell transplantation, as well as SER-603 and SER-147, which target gastrointestinal microbiome disruption and certain infection risks in patients with metabolic disease and chronic liver disease. Founded in 2010 and based in Cambridge, Massachusetts, the company was previously known as Seres Health, Inc. before adopting its current name in 2015.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MCRB
|
$7.22
|
38.3% Upside
|
Undervalued
|
$17
|
225.7% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-1.1x
|
1.9x
|
45.0x
|
49.485 M
|
102.2 M
|
61.9%
|
87.5%
|
-13.8
|
—
|
90.3%
|
